GET DAILY SIGNALSAlbertsons (ACI) Q4 Earnings: Resilience Amid Pharmacy Pressures and Solid Guidance
Key Takeaways
- Albertsons reported Q4 fiscal 2025 net sales and other revenue of $20.3 billion, up from $18.8 billion in the prior-year 12-week period, boosted by a 53rd week.
- Identical sales grew 0.7%, pressured by pharmacy headwinds from the Inflation Reduction Act (IRA, a U.S. law capping certain drug prices) and GLP-1 (glucagon-like peptide-1 drugs for diabetes/weight loss) mix shifts.
- Adjusted EBITDA reached $903 million, exceeding expectations despite challenges; full-year adjusted EBITDA hit $3.9 billion.
- Adjusted EPS was $0.48, beating consensus estimates of $0.43 by $0.05.
- Net loss of $481 million due to a $600 million opioid settlement charge; shares fell over 3% post-earnings.
- FY2026 guidance includes identical sales of 0%-1%, adjusted EBITDA of $3.85-$3.925 billion, and raised dividend plus $2 billion buyback authorization.
Earnings Context and Why It Matters to Investors
As someone who follows the grocery and pharmacy space closely, I see Albertsons Companies (ACI)—one of the largest U.S. food and drug retailers with over 2,200 stores—navigating a tough competitive landscape from players like Walmart, Costco, and Amazon. This Q4 fiscal 2025 report, which ended February 28, 2026, wraps up a year marked by macroeconomic pressures, digital acceleration, and regulatory shifts like the IRA affecting reimbursements. From what I see, investors are paying particular attention to pharmacy dynamics, now a critical growth area, and identical sales trends as indicators of consumer health. The strong adjusted profitability highlights operational efficiency, but factors like the opioid settlement and forward guidance will influence perceptions around capital returns and potential mergers in this consolidating industry.
Breaking Down the Reported Results
Albertsons delivered net sales and other revenue of $20.3 billion for the 13-week Q4 fiscal 2025, compared to $18.8 billion in the prior-year 12-week quarter. This uptick included about $1.4 billion from the extra 53rd week, plus 0.7% identical sales growth. Digital sales increased 16%, though pharmacy sales encountered steeper-than-expected headwinds: roughly 105 basis points from IRA pricing and 40 basis points from GLP-1 moderation, totaling around 145 basis points of impact.
Adjusted EBITDA rose to $903.4 million (including about $68 million from the extra week), up from $855.1 million last year and ahead of analyst forecasts. Adjusted net income came in at $252 million, or $0.48 per share, surpassing the consensus of $0.43. On a GAAP basis, though, the company posted a net loss of $480.8 million, or ($0.94) per share, primarily due to a $599.8 million pre-tax opioid settlement charge. For the full year, net sales reached $83.2 billion, up from $80.4 billion, with 2% identical sales growth and adjusted EBITDA of $3.9 billion.
One thing that stands out here is how the adjusted metrics held up well despite the pharmacy pressures—I also checked this using Tickeron’s AI Screener to compare ACI against peers in the industry.
Market Reaction and Investor Sentiment
Post-earnings on April 14, 2026, ACI shares declined 3.03% to $16.34, with further drops in after-hours and premarket trading. The reaction seemed driven by revenue coming in slightly below some estimates (around $20.3 billion versus $20.49 billion expected in certain spots), pharmacy challenges surpassing forecasts, and the opioid charge eclipsing the positive adjusted EPS and EBITDA results. Even with supportive capital return moves—a 13% dividend increase to $0.17 per share and a reset $2 billion buyback—sentiment has turned cautious amid broader grocery sector issues like margin compression.
Forward Outlook and Factors I'm Watching
Looking ahead, Albertsons provided fiscal 2026 guidance for a 53-week year ending around February 2027, forecasting identical sales growth of 0%-1% (or 1.5%-2.5% excluding IRA impacts). This reflects persistent pharmacy reimbursement issues and easing GLP-1 demand.
Adjusted EBITDA is projected at $3.85-$3.925 billion, bolstered by a $2 billion three-year productivity program, AI and digital investments, and supply chain improvements. The adjusted EPS range is $2.22-$2.32, with capital expenditures of $2.0-$2.2 billion earmarked for remodels (94 completed in FY2025), new stores, and technology platforms. The effective tax rate is expected at 24%-25%.
In my view, key areas to monitor include pharmacy trends under the IRA, digital and loyalty program growth (with 49.8 million members previously), fuel margins, and Own Brands performance in an inflationary environment. Capital allocation will remain pivotal—FY2025 returned over $1.8 billion through buybacks and dividends, and the new authorization signals confidence. Broader opportunities could emerge from M&A in the fragmented grocery sector, labor trends, and consumer spending patterns.
Why I Use Tickeron’s AI Screener in My Analysis
As part of my regular research process, I rely on Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—such as industry peers, market cap, indicators, price patterns, and performance metrics. This helps pinpoint trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual methods. If you're screening for names like ACI, it's a practical way to streamline your workflow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ACI's Stochastic Oscillator entering oversold zone
The Stochastic Oscillator for ACI moved into oversold territory on October 30, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ACI as a result. In 52 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
ACI moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ACI crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 33%.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACI advanced for three days, in 144 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.
Bearish Trend Analysis
The 10-day RSI Indicator for ACI moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 16 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Moving Average Convergence Divergence Histogram (MACD) for ACI turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 29 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ACI broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ACI entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. ACI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.936) is normal, around the industry mean (59388.852). ACI's P/E Ratio (81.750) is considerably higher than the industry average of (11.869). Projected Growth (PEG Ratio) (1.212) is also within normal values, averaging (0.979). ACI has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.017). P/S Ratio (0.080) is also within normal values, averaging (10.259).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in production and distribution of thermal coal
Industry FoodRetail
Advertisement